FindTrial
Sign In

Patient with diabetic retinopathy undergoing intravitreal Avastin injection.

Vitreo retinal interface changes after Intravitreal Bevacizumab (Avastin) injection in Proliferative Diabetic Retinopathy using Spectral Domain Optical Coherence Tomography.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/04/012956
Enrollment
20
Registered
2018-04-03
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: NIL: NIL

Sponsors

Giridhar Eye Institute
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients with active fibrovascular proliferation due to proliferative diabetic retinopathy with or without tractional retinal detachment.

Exclusion criteria

Exclusion criteria: (a) patients below 18 years of age (b) dense vitreous haemorrhage (c) history of thromboembolic event or heart attack.

Design outcomes

Primary

MeasureTime frame
To document the changes at vitreo retinal interface by spectral domain optical coherence tomography, in patients with PDR after intravitreal Bevacizumab injection.Timepoint: 12 Months—

Secondary

MeasureTime frame
To determine any decrease in intra and post operative complication in patients with preoperative adjuvant bevacizumab injection and visual outcome in these patients.Timepoint: 12 Months—

Countries

India

Contacts

Public ContactDr Jaitra P G

Giridhar Eye Institute

jaitrapg@gmail.com9986958525

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026